Archive for June, 2008

Morphine Tablets Recalled

Saturday, June 14th, 2008

ETHEX Corporation is recalling one lot of 60 mg morphine sulfate tablets due to a risk of overdose. The tablets were manufactured with double the dose of morphine sulfate that is on the label, which could cause serious adverse reactions.

The lot affected by the recall is number 91762. No additional lots are being recalled.

The morphine tablets were released between April 15 and April 27, 2008. They are under the ETHEX label.

As with all opioid medication, the consequences of an overdose can be fatal. An overdose of morphine may result in difficulty breathing and lowered blood pressure.

To this date, the U.S. Food and Drug Administration (FDA) has not received any reports of adverse side effects.

Defective drug attorneys are working to help prevent serious consequences of faulty prescription medication by holding drug manufactures responsible for their negligence.

Study Shows Paxil Causes Increased Birth Defects

Wednesday, June 11th, 2008

New studies show that Paxil causes increased birth defects when taken during the first trimester of pregnancy.  In many cases the most prominent birth defects were atrial and ventricular septal heart defects (holes in the heart chamber walls).  Other possible birth defects may include:

 

Difficulties with breathing

Seizures

Vomiting

Low blood sugar

Tremor

Irritability

 

If you or a loved one has been harmed by a dangerous drug or product, contact the attorneys at Cappolino Dodd Krebs LLP today, at 1-800-460-0606.

Noven Recalls Daytrana Methylphenidate Transdermal System

Wednesday, June 11th, 2008

On June 9, 2008, Noven Pharmaceuticals, Inc. voluntarily recalled two lots of the Daytrana Methylphenidate Transdermal System. Daytrana is the only transdermal patch approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Noven is recalling the product due to a problem with the release liner removal specifications. Do to the malfunction, patients could have difficulties removing the patch resulting in damage to the product.

Any damaged or hard to remove Daytrana patch should be discarded.

Noven is working with the U.S. Food and Drug Administration to incorporate needed changes to the Daytrana patch.

Defective drug attorneys are working on cases that involve faulty prescription drugs.